Pfizer is in advanced talks to acquire U.S. cancer drug company Medivation for close to $14 billion, as it seeks to boost its oncology portfolio, people familiar with the matter said on Sunday.
Pfizer has agreed to pay a little more than $80 per share for Medivation, one of the people said, a substantial premium to the $52.50 offer for Medivation that France's Sanofi SA made in April, which eventually resulted in the company putting itself up for sale. Medivation shares ended trading in Ne...
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle12
03:00 Carrier incentives stir debate over 'rewarding' offshoring11
01:02 A company Trump attacked will receive state tax breaks to keep jobs in the U.S11
02:34 Carrier agrees to keep 'close to 1,000 jobs' in Indianapolis16